Literature DB >> 3143865

Establishment and characterization of a human lymphoma cell line (WSU-NHL) with 14;18 translocation.

A N Mohamed1, A al-Katib.   

Abstract

The WSU-NHL cell line was established from a malignant pleural effusion occurring in a 46-yr-old female with nodular histiocytic (follicular, large cell) lymphoma. The established cells grow in clumps with a doubling time of 57 h. On light microscopy, cells exhibited primitive lymphoblastoid morphologic features with few cytoplasmic blebs. DNA histogram generated by flow cytometry indicated a hypodiploid stemline (0.93). Immunologic study revealed a mature B-cell phenotype with surface and cytoplasmic IgG lambda and reactivity with monoclonal antibodies to B-cell antigens (B1, B4, BL1, BL3, BL4, BL7, HLA-DR, CALLA and Leu-10). The cells were negative for T-cell and myeloid-monocyte antigens as well as Epstein-Barr virus nuclear antigen (EBNA). Cytogenetic analysis revealed 45,XX metaphases with complex abnormalities including t(14;18) (q32;q21). The phorbol ester, 12-O tetradecanoylphorbol 13 acetate (TPA) (1.6 x 10(-8) M) and interferon gamma (IFN-gamma) (500 U/ml) inhibited cell growth and induced differentiation to a more mature phenotype. The WSU-NHL cell line provides a continuous source of cells for molecular and immunologic studies of human lymphoma as well as the regulation of its growth and differentiation by biologic agents.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143865     DOI: 10.1016/0145-2126(88)90037-9

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.

Authors:  Shruti Bhatt; Brittany M Ashlock; Yasodha Natkunam; Victoria Sujoy; Jennifer Rose Chapman; Juan Carlos Ramos; Enrique A Mesri; Izidore S Lossos
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

2.  Establishment and characterisation of an Epstein-Barr virus negative B immunoblastic lymphoma cell line.

Authors:  Y S Ho; L F Sheu; J A Ng; S M Hsu
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

Review 3.  Targeting CD19 in B-cell lymphoma: emerging role of SAR3419.

Authors:  Ali Raufi; Abdul Shukkur Ebrahim; Ayad Al-Katib
Journal:  Cancer Manag Res       Date:  2013-08-27       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.